0 results for 'GlaxoSmithKline'
Defendant Granted Disclosure of Documents Wrongly Withheld as Privileged, Work Product
Former GSK Patent Leader Moves to Troutman Pepper
Duke Fitch started at the company as a medicinal chemist and rose to vice president of U.S. pharmaceutical patents after earning his law degree.Dechert Partner Who Repped J&J, 3M and BP in High-Profile Trials Moves to Paul Weiss
Kimberly Branscome joins Paul Weiss's Los Angeles office after nearly four years at Dechert.No Jurisdiction Over Defendant; State Lacked Connections to Party
Deal Watch: Kirkland, Akin Drive Energy Deals as Big Law Leans Into Sector for M&A
Four of the five announced M&A deals of more than $1 billion in the past week involved the energy and infrastructure sectors.View more book results for the query "GlaxoSmithKline"
Pharmaceutical Legal and Regulatory Trends To Watch in 2024
This article highlights several notable legal and regulatory developments in 2023 and discusses developments that will continue to shape the pharmaceutical industry in 2024.Shearman's Co-Managing Partner Leads Team Move to Linklaters in New York
The six-person team is departing ahead of the firm's merger with Allen & Overy, which will see A&O leaders take charge of the combined firm.Deal Watch: Big Law Dealmakers Are Evaluating These Factors to Assess 2024 Market
Frank Aquila, partner in Sullivan & Cromwell's corporate group, said the tempering of inflation and the broader economic news that ushers in could be a boon for M&A in 2024.Debra D. Pierce v. Archer Daniels Midland, Co., et al.
'Illogical and Unfair,' Justice Thomas Says of DuPont's Treatment in MDL
Justice Clarence Thomas dissented from the Supreme Court's denial of the chemical company's appeal of a multidistrict litigation trial.Download Now
Download Now
Download Now
Download Now